tci Medicare Compliance & Reimbursement - 2004 Issue 9
Pharmaceuticals: Watch For Tighter Medicaid Rebate Enforcement
Subscribe or sign in to view the full article.
Article Overview
This article discusses a congressional investigation into Medicaid pharmaceutical reimbursement and rebate enforcement. It explains why Medicaid drug pricing has become a focus for government review, summarizes the broad questions being raised about pricing benchmarks and reporting, and describes how the issue may affect drugmakers, state Medicaid programs, and those who follow federal healthcare policy.
Why This Topic Matters
The piece is relevant to readers tracking Medicaid payment policy, pharmaceutical reimbursement oversight, and federal or state efforts to tighten rebate collection. It helps stakeholders understand the policy environment surrounding drug pricing review and potential changes to Medicaid administration.
What You Will Learn
- Why Medicaid drug pricing is drawing congressional attention
- What broad reimbursement and rebate issues are under government review
- How federal and state Medicaid oversight may affect pharmaceutical stakeholders
- What general policy questions are being raised about drug pricing methods and reporting
Who Should Read This
- Medical coders and billing professionals
- Healthcare compliance teams
- Pharmaceutical manufacturers
- Medicaid policy analysts
- Healthcare attorneys and consultants
Subscribe or sign in to view the full article.
Thank you for choosing Find-A-Code, please Sign In to remove ads.
Quick, Current, Complete - www.findacode.com